Literature DB >> 25948621

Surrogate markers for time-varying treatments and outcomes.

Jesse Y Hsu1, Edward H Kennedy2, Jason A Roy2, Alisa J Stephens-Shields2, Dylan S Small3, Marshall M Joffe2.   

Abstract

BACKGROUND: A surrogate marker is a variable commonly used in clinical trials to guide treatment decisions when the outcome of ultimate interest is not available. A good surrogate marker is one where the treatment effect on the surrogate is a strong predictor of the effect of treatment on the outcome. We review the situation when there is one treatment delivered at baseline, one surrogate measured at one later time point, and one ultimate outcome of interest and discuss new issues arising when variables are time-varying.
METHODS: Most of the literature on surrogate markers has only considered simple settings with one treatment, one surrogate, and one outcome of interest at a fixed time point. However, more complicated time-varying settings are common in practice. In this article, we describe the unique challenges in two settings, time-varying treatments and time-varying surrogates, while relating the ideas back to the causal-effects and causal-association paradigms.
CONCLUSION: In addition to discussing and extending popular notions of surrogacy to time-varying settings, we give examples illustrating that one can be misled by not taking into account time-varying information about the surrogate or treatment. We hope this article has provided some motivation for future work on estimation and inference in such settings.
© The Author(s) 2015.

Entities:  

Keywords:  Causal inference; observational studies; randomization; surrogacy; time-varying

Mesh:

Substances:

Year:  2015        PMID: 25948621      PMCID: PMC4506229          DOI: 10.1177/1740774515583500

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  16 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  An experimental design for the development of adaptive treatment strategies.

Authors:  S A Murphy
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

3.  Identifiability and exchangeability for direct and indirect effects.

Authors:  J M Robins; S Greenland
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

4.  Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Authors:  Jeremy M G Taylor; Yue Wang; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

5.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Authors:  Li Qin; Peter B Gilbert; Dean Follmann; Dongfeng Li
Journal:  Ann Appl Stat       Date:  2008-03       Impact factor: 2.083

6.  Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Authors:  Erin E Gabriel; Peter B Gilbert
Journal:  Biostatistics       Date:  2013-12-13       Impact factor: 5.899

7.  Related causal frameworks for surrogate outcomes.

Authors:  Marshall M Joffe; Tom Greene
Journal:  Biometrics       Date:  2009-06       Impact factor: 2.571

8.  Estimating the proportion of treatment effect explained by a surrogate marker.

Authors:  D Y Lin; T R Fleming; V De Gruttola
Journal:  Stat Med       Date:  1997-07-15       Impact factor: 2.373

9.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

10.  Surrogate measures and consistent surrogates.

Authors:  Tyler J Vanderweele
Journal:  Biometrics       Date:  2013-09       Impact factor: 2.571

View more
  3 in total

1.  University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).

Authors:  Michael Daniels; Constantine Frangakis; Vivek Charu; Debashis Ghosh
Journal:  Clin Trials       Date:  2015-06-10       Impact factor: 2.486

2.  Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

Authors:  Isabelle R Weir; Jennifer R Rider; Ludovic Trinquart
Journal:  Pharm Stat       Date:  2021-08-04       Impact factor: 1.894

3.  The Influence of Upper and Lower Extremity Strength on Performance-Based Sarcopenia Assessment Tests.

Authors:  Michael O Harris-Love; Kimberly Benson; Erin Leasure; Bernadette Adams; Valerie McIntosh
Journal:  J Funct Morphol Kinesiol       Date:  2018-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.